Bahrain vs Montenegro: HIV/AIDS deaths averted by antiretroviral therapy
HIV/AIDS deaths averted by antiretroviral therapy over time
- Bahrain
- Montenegro
How they compare
Bahrain currently reports 20.62 deaths against 18.1 deaths in Montenegro, a difference of 2.52 deaths.
That makes Bahrain's figure about 1.1 times Montenegro's.
The two have swapped places 5 times across 35 shared years of data; in 1990 it was Montenegro ahead.
Bahrain ranks 147th and Montenegro ranks 148th of 157 countries.
Across the 4 decades both report, Bahrain averaged higher in 2 and Montenegro in 2.
Head to head by decade
| Decade | Bahrain | Montenegro | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0.0409 deaths | 0.0409 deaths | Montenegro |
| 2000s | 3.99 deaths | 2.41 deaths | 1.58 deaths | Bahrain |
| 2010s | 7.14 deaths | 8.06 deaths | 0.9155 deaths | Montenegro |
| 2020s | 17.51 deaths | 14.86 deaths | 2.65 deaths | Bahrain |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Bahrain or Montenegro?
- Bahrain, at 20.62 deaths against 18.1 deaths in Montenegro as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Bahrain and Montenegro?
- 2.52 deaths, with Bahrain ahead.
- How many years of comparable data are there for Bahrain and Montenegro?
- 35 years are reported by both, from 1990 to 2024.
- How do Bahrain and Montenegro rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Bahrain ranks 147th and Montenegro ranks 148th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.